Free tool
FAERS Monitor: Crinone
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020756 or its brand name (Crinone, Progesterone). Reports on generic versions are filed under their own applications.
Reports
20,427
Serious
11,188
55% of reports
Hospitalization
3,238
Death reported
490
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache1,893
- off label use1,733
- drug ineffective1,678
- fatigue1,598
- pain1,348
- nausea1,325
- exposure during pregnancy945
- rash932
- foetal exposure during pregnancy915
- hypersensitivity823
- dizziness818
- maternal exposure during pregnancy807
- hyperhidrosis793
- product use issue789
- diarrhoea728
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 138 |
| 2005 | 157 |
| 2006 | 146 |
| 2007 | 118 |
| 2008 | 174 |
| 2009 | 241 |
| 2010 | 278 |
| 2011 | 246 |
| 2012 | 393 |
| 2013 | 365 |
| 2014 | 471 |
| 2015 | 836 |
| 2016 | 1,229 |
| 2017 | 993 |
| 2018 | 1,093 |
| 2019 | 1,241 |
| 2020 | 1,288 |
| 2021 | 1,252 |
| 2022 | 1,426 |
| 2023 | 1,606 |
| 2024 | 1,998 |
| 2025 | 2,234 |
| 2026 | 2,504 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,033,732 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| exposure during pregnancySignal | 945 | 15.9 | 14.9 | 13,001 |
| foetal exposure during pregnancySignal | 915 | 11.7 | 11.0 | 8,887 |
| maternal exposure during pregnancySignal | 807 | 9.4 | 8.8 | 6,019 |
| hyperhidrosisSignal | 793 | 6.4 | 6.0 | 3,586 |
| hypersensitivitySignal | 823 | 4.6 | 4.3 | 2,310 |
| product use issueSignal | 789 | 4.3 | 4.0 | 2,032 |
| headacheSignal | 1,893 | 3.1 | 3.0 | 2,792 |
| painSignal | 1,348 | 2.3 | 2.1 | 975 |
| rashSignal | 932 | 2.2 | 2.1 | 623 |
| fatigueSignal | 1,598 | 2.1 | 2.0 | 973 |
| off label useSignal | 1,733 | 2.0 | 1.9 | 956 |
| nausea | 1,325 | 1.7 | 1.6 | 418 |
| dizziness | 818 | 1.7 | 1.6 | 235 |
| drug ineffective | 1,678 | 1.3 | 1.3 | 132 |
| diarrhoea | 728 | 1.2 | 1.1 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.